NCT03473132View on ClinicalTrials.gov

Assessment of Coagulation Factor Levels in Left Ventricular Device (LVAD )Patients Following Temporary Warfarin Reversal With Four Factor Prothrombin Complex Concentrate (4F-PCC)

PHASE4UnknownINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 15, 2018

Primary Completion Date

December 31, 2021

Study Completion Date

March 31, 2022

Conditions
AnticoagulationAnticoagulation Reversal
Interventions
DRUG

four factor prothrombin complex concentrate

After treatment with 4F-PCC, coagulation factor levels will be assessed. Time to return to anticoagulation target INR will also be determined.

Trial Locations (1)

02115

RECRUITING

Brigham and Women's Hospital, Boston

Sponsors

Collaborators (1)

CSL Behring
All Listed Sponsors
collaborator

CSL Behring

INDUSTRY

lead

Brigham and Women's Hospital

OTHER